• Skip to main content
  • Skip to footer
cnb1383_liver-model-drug-safety_webinar_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Imperial College London to present HBV data on CN Bio immune-competent liver model at AASLD The Liver Meeting

CN Bio Innovations Ltd, an expert in developing human organ chip platforms to test and develop therapeutics for serious diseases, has announced that new data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be presented in the late-breaking poster session at The Liver Meeting® 2015, San Francisco USA (13-17 November, 2015).

November 2, 2015

New advances in the pre-clinical evaluation of Hepatitis B therapies

Welwyn Garden City, UK, 2 Nov 2015: CN Bio Innovations Ltd, an expert in developing human organ chip platforms to test and develop therapeutics for serious diseases, has announced that new data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be presented in the late-breaking poster session at The Liver Meeting® 2015, San Francisco USA (13-17 November, 2015).

Dr Marcus Dorner (Imperial College London), Lead Principle Investigator for the study, and Dr David Hughes, CN Bio’s Chief Technical Officer, will be available during the session which takes place on November the 16th from 12:30 – 2:00 pm to discuss the poster presentation entitled, “Microfluidic liver cultures as preclinical tool for the study of hepatitis B and C virus as well as malaria”.

Category iconBusiness

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
  • Why the FDA animal testing phase-out for monoclonal antibodies? May 1, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research April 29, 2025
Cyber Essentials Logo